Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said ...

LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next ...

The Swiss drugmaker announced its biggest deal in a decade on Sunday, as its set to buy Avidity Biosciences for about $12 billion. "We have adequate firepower to do deals like this and to bolster the ...

Yesterday, the MS/MBA program at Harvard Business School (HBS) hosted Novartis CEO Dr. Vas Narasimhan for what proved to be a captivating and wide-ranging discussion, led by Dr. Christiana Bardon ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

The business of manufacturing never stops. Industrial companies merge, invest and strategically expand to keep competitive, ...